Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.

Kewaunee Scientific agreed to acquire Nycom for an initial base purchase price of $55 million, subject to EBITDA-based and customary post-closing adjustments. Consideration includes a $20 million subordinated note, $5 million in newly issued Kewaunee shares, and a remaining cash portion funded with cash on hand and financing expected from PNC Bank. The companies say the deal will combine Kewaunee's manufacturing capabilities with Nycom's laboratory design, distribution, and project-delivery platform; closing is expected in the fourth quarter of fiscal 2027, subject to customary conditions.

Analysis

The strategic value is control of project execution and customer access—not simply added product sales. If Nycom directs more projects toward Kewaunee’s products, KEQU may capture a larger share of project economics and gain earlier input into product design. But the same shift risks alienating independent dealers who value supplier neutrality; any channel leakage could offset owned-platform growth. Management says partners remain important, but retention is unproven.

The headline $55 million base price is not enough to judge value: Nycom EBITDA, working-capital needs, and the EBITDA-linked adjustments are undisclosed. The “greater of” trailing-12-month or 2026 EBITDA reference may raise consideration if the stronger period sets the adjustment. Funding also adds cash borrowing, a subordinated seller note, and equity issuance; quantify pro forma leverage, interest burden, covenants, dilution, and purchase multiple before underwriting accretion.

Near term, the announcement may support the strategic narrative, but execution and financing terms—not stated synergy—should drive valuation. The close is not expected until Q4 fiscal 2027, leaving a long window for diligence, financing, and customer-retention risk. Over 6–18 months, the model could become a regional roll-up platform, but integration capacity and disciplined pricing will determine whether that creates returns or consumes capital. The release is promotional; verify the transaction economics and post-close results independently.

Key Decisions for Investors

• Do not chase the strategic announcement alone. Treat KEQU as a watch pending disclosure of Nycom revenue and EBITDA, the final purchase-price adjustment, financing rate and covenants, and pro forma leverage and dilution.
• Potential conditional long: consider KEQU only if the stock weakens on financing concerns while diligence shows the fully adjusted purchase multiple and debt burden are manageable, and Nycom’s customers and independent dealer relationships are holding. No trade is warranted without those inputs.
• Track the closing timetable and any revised financing or purchase terms through Q4 fiscal 2027. A delay, material price increase, or evidence of dealer/customer attrition would undermine the thesis; disclosed retention, cross-selling, and cash generation would strengthen it.
• Falsification after closing: monitor acquired-business EBITDA versus the purchase-price reference, cash conversion after working capital, incremental interest expense, and evidence that KEQU’s independent channel is contracting. Do not infer success from revenue growth alone.